

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**CHANGE OF
(1) COMPANY SECRETARY,
(2) AUTHORISED REPRESENTATIVE AND
(3) PROCESS AGENT**

The board (the “**Board**”) of directors (the “**Directors**”) of China NT Pharma Group Company Limited (the “**Company**”) announces that Ms. Li Yifang (“**Ms. Li**”) tendered her resignation (the “**Resignation**”) as (1) the company secretary of the Company, (2) the authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) and (3) the agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) with effect from 31 August 2026.

Ms. Li confirmed that she has no disagreement with the Board and there are no circumstances related to her Resignation which need to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board further announces that, following the resignation of Ms. Li, Mr. Wong Chi Keung (“**Mr. Wong**”) has been appointed as the Company Secretary, the Authorised Representative and the Process Agent of the Company with effect from 31 August 2026.

Mr. Wong is currently a Director of two Hong Kong Certified Public Accountants (“**CPA**”) firms and joint company secretary of Canggang Railway Limited (stock code: 2169). Mr. Wong was employed by two international accounting firms for more than 7 years, and has over 16 years of experience in finance, auditing, and corporate compliance. He possesses solid experience in corporate governance, regulatory compliance, corporate secretarial and advisory on the Hong Kong Listing Rules and the Companies Ordinance. Mr. Wong has been responsible for overseeing compliance matters, liaising with boards and audit committees, and ensuring timely filings and disclosures for listed and regulated entities. He holds a Bachelor of Accountancy degree from City University of Hong Kong and is a practicing member of Hong Kong Institute of Certified Public Accountants.

Ms. Li has discharged her duties diligently and conscientiously during her tenure of office, and the handover of the work for which she was responsible has been completed. The Board wishes to take this opportunity to express its gratitude to Ms. Li for her contribution during her tenure of office and express its warmest welcome to Mr. Wong for taking up the appointment.

By Order of the Board of
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 31 August 2026

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.